Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Quantum AMC’s Christy Mathai sees private banks, insurance as long-term bets amid earnings risks
Christy Mathai, Fund Manager-Equity at Quantum AMC, believes elevated crude and input costs could lead to earnings downgrades across sectors over the next year, especially in consumer discretionary. Despite near-term uncertainty, he remains constructive on private banks, life insurance and select real estate plays from a longer-term perspective. Mathai also said valuations in power and data centre-related themes remain expensive despite strong structural growth opportunities.
Margin pressure, slower growth outlook may cap upside for Sun Pharma stock
Sun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and lower milestone income. The company anticipates range-bound margins and moderating revenue growth in FY27, driven by specialty launches and R&D spending. Domestic formulations remain robust, while US segment recovery is expected to be gradual.
LIC emerges as highest profit-making financial company in March quarter
Life Insurance Corporation of India has achieved the highest profit in the Indian financial sector for the March quarter. The company reported a significant jump in net profit. State Bank of India and HDFC Bank followed with substantial profits. LIC's assets under management and premium income also saw growth. Vodafone Idea recorded a record quarterly profit due to statutory relief.
Why organized players like Titan Company could emerge bigger winners in India’s evolving gold market
India's gold market is rapidly formalizing despite high prices and tax hikes. Resilient consumer demand, especially for investment, favors organized players like Titan. Titan, leveraging Tanishq's brand strength, is projected for significant growth, modeling a sales/EBITDA/PAT CAGR of ~15%/20%/24% over FY26–28.
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration deal
Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on the acquisition of Organon, with completion targeted for the last quarter of FY2027. This strategic move is set to enhance Sun Pharma's global presence and product portfolio across key therapeutic areas.
Sun Pharma guides for slower FY27 growth amid regulatory, macro challenges
Sun Pharma forecasts high single-digit revenue growth for FY27 after an 11.9% increase in FY26 revenue. The company aims to expand its innovative portfolio amid regulatory challenges and compliance issues, while also focusing on acquisitions and new product launches in the obesity-drug market.
Aditya Birla Capital Plans To Use Rs 3,500 Crore To Drive Lending Business Growth
Earlier this week, the financial services arm of Aditya Birla Group announced a Rs 4,000 crore preferential issue of equity shares to the group companies and International Finance Corporation (IFC).
Retail health premium growth rises to 31% YoY in April 2026, anchoring non-life insurance sector: Kotak Institutional Securities
Indian non-life insurance saw robust growth in April 2026. Retail health premiums surged 31 percent year-on-year. Motor insurance also performed well. Private players and standalone health insurers are gaining market share from public sector companies. Commercial lines faced challenges, though marine and engineering segments showed resilience. This indicates a dynamic shift in the insurance landscape.
Sun Pharma Q4 Results: Drugmaker shares fall after earnings miss; US sales at $459 million
Sun Pharma's US formulations sales fell 1.1% from last year to $459 million during the March quarter. For the full year, the growth was a negative 0.9%.
Aditya Birla Group stocks: Grasim hits new peak; Voda Idea up 46% in 1-mth
Grasim is the flagship company of Aditya Birla Group, which is led by Kumar Mangalam Birla; while, the group holds substantial stake in Vodafone Idea.
Aditya Birla Capital plans to use Rs 3,500 crore to drive business growth
Aditya Birla Capital plans to invest Rs 3,500 crore from its recent fundraise into business expansion. Another Rs 500 crore will support general corporate needs and subsidiary investments. The company is raising Rs 4,000 crore through a preferential issue. Grasim Industries will contribute Rs 2,880 crore. IFC will invest Rs 920 crore.
High gold prices, import duty hike to drag jewellery demand: Crisil
Indian organized gold jewellery retailers anticipate a 13-15% sales volume decline this fiscal due to high gold prices and import curbs. Despite this, robust revenue growth of 20-25% is expected, driven by higher realisations, leading to stable credit profiles.